Myriad Genetics, Inc. (0K3W.L)
USD 8.13
(0.12%)
USD 8.13
(0.12%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2022 | 130.9 Million USD | 65.07% |
| 2021 | 79.3 Million USD | -64.72% |
| 2020 | 224.8 Million USD | -3.73% |
| 2019 | 233.5 Million USD | 0.0% |
| 2018 | 233.5 Million USD | 2410.75% |
| 2017 | 9.3 Million USD | -90.62% |
| 2016 | 99.1 Million USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | -100.0% |
| 1996 | 100 Thousand USD | -80.0% |
| 1995 | 500 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q1 | 146.5 Million USD | 11.92% |
| 2023 Q3 | 183.6 Million USD | -1.71% |
| 2023 Q2 | 186.8 Million USD | 27.51% |
| 2022 Q4 | 130.9 Million USD | 6.16% |
| 2022 Q1 | 76.5 Million USD | -3.53% |
| 2022 Q3 | 123.3 Million USD | 41.08% |
| 2022 Q2 | 87.4 Million USD | 14.25% |
| 2022 FY | 130.9 Million USD | 65.07% |
| 2021 FY | 79.3 Million USD | -64.72% |
| 2021 Q2 | 83.9 Million USD | -58.75% |
| 2021 Q3 | 80.7 Million USD | -3.81% |
| 2021 Q4 | 79.3 Million USD | -1.73% |
| 2021 Q1 | 203.4 Million USD | -26.14% |
| 2020 Q1 | 281.1 Million USD | -0.95% |
| 2020 Q3 | 278.1 Million USD | -1.14% |
| 2020 Q2 | 281.3 Million USD | 0.07% |
| 2020 FY | 224.8 Million USD | -3.73% |
| 2020 Q4 | 275.4 Million USD | -0.97% |
| 2019 Q4 | 283.8 Million USD | -1.32% |
| 2019 Q2 | 233.5 Million USD | -11.35% |
| 2019 FY | 233.5 Million USD | 0.0% |
| 2019 Q1 | 263.4 Million USD | -3.62% |
| 2019 Q3 | 287.6 Million USD | 23.17% |
| 2018 FY | 233.5 Million USD | 2410.75% |
| 2018 Q1 | 69.3 Million USD | 60.42% |
| 2018 Q2 | 9.3 Million USD | -86.58% |
| 2018 Q3 | 258 Million USD | 2674.19% |
| 2018 Q4 | 273.3 Million USD | 5.93% |
| 2017 Q4 | 43.2 Million USD | -41.62% |
| 2017 FY | 9.3 Million USD | -90.62% |
| 2017 Q3 | 74 Million USD | -25.33% |
| 2017 Q2 | 99.1 Million USD | -40.69% |
| 2017 Q1 | 167.1 Million USD | -18.09% |
| 2016 Q2 | - USD | 0.0% |
| 2016 FY | 99.1 Million USD | 0.0% |
| 2016 Q4 | 204 Million USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q2 | - USD | 100.0% |
| 2015 Q1 | -36.55 Million USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1997 Q3 | - USD | -100.0% |
| 1997 FY | - USD | -100.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 Q1 | 200 Thousand USD | -33.33% |
| 1997 Q2 | 100 Thousand USD | -50.0% |
| 1996 Q2 | 500 Thousand USD | -16.67% |
| 1996 Q1 | 600 Thousand USD | 0.0% |
| 1996 FY | 100 Thousand USD | -80.0% |
| 1996 Q4 | 300 Thousand USD | -25.0% |
| 1996 Q3 | 400 Thousand USD | -20.0% |
| 1995 Q4 | 600 Thousand USD | 0.0% |
| 1995 FY | 500 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | -0.642% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -129.697% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 66.251% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -186.477% |
| bluebird bio, Inc. | 224.41 Million USD | 41.672% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -253.03% |
| Imunon, Inc. | 1.13 Million USD | -11389.582% |
| Editas Medicine, Inc. | 24.37 Million USD | -437.092% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 98.99% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 93.374% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 49.322% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -294.325% |
| Verastem, Inc. | 40.08 Million USD | -226.548% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 98.373% |
| Waters Corporation | 2.3 Billion USD | 94.322% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.582% |
| Biogen Inc. | 7.18 Billion USD | 98.179% |
| Nektar Therapeutics | 112.62 Million USD | -16.226% |
| Perrigo Company plc | 3.63 Billion USD | 96.397% |
| Dynavax Technologies Corporation | 252.41 Million USD | 48.142% |
| Illumina, Inc. | 1.48 Billion USD | 91.209% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -3941.831% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -12990.0% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 24.663% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -456.098% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 77.929% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -290.571% |
| Evolus, Inc. | 120.35 Million USD | -8.758% |
| Adicet Bio, Inc. | 17.7 Million USD | -639.423% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -4158.295% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 95.157% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 73.901% |
| FibroGen, Inc. | 89.69 Million USD | -45.936% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 95.214% |
| OPKO Health, Inc. | 222.03 Million USD | 41.045% |
| Homology Medicines, Inc. | 43.17 Million USD | -203.178% |
| Geron Corporation | 35.05 Million USD | -273.456% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 94.413% |
| Exelixis, Inc. | 189.94 Million USD | 31.085% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -13885.043% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -35.301% |
| Zoetis Inc. | 6.56 Billion USD | 98.006% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 26.49% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -2873.648% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 81.937% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -282.86% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 90.653% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 88.442% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 91.269% |
| Blueprint Medicines Corporation | 610.96 Million USD | 78.575% |
| Insmed Incorporated | 1.19 Billion USD | 89.031% |
| TG Therapeutics, Inc. | 100.11 Million USD | -30.746% |
| Incyte Corporation | 29.16 Million USD | -348.872% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 70.683% |